Chinese innovative drug companies presented strong clinical research at the American Society of Clinical Oncology (ASCO) meeting, yet their stock prices continued to fall. Despite high-quality data, including significant advancements in areas like ADC+IO combination therapies, the market has not responded positively. Factors such as a shift in investor focus to tech sectors, geopolitical tensions, and stricter global market standards are contributing to this disconnect, prompting a re-evaluation of the investment value of these companies. AI
RANK_REASON The article discusses market reactions and industry sentiment regarding clinical trial results, rather than announcing a new release or breakthrough.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →